Core Viewpoint - The article discusses ongoing legal actions against Nuotai Bio (688076) for false statements made in their financial reports, particularly regarding a technology transfer that inflated their reported revenue and profits in 2021 [1][2][3][4] Group 1: Legal Proceedings - The Shanghai Jucheng Law Firm, represented by lawyer Xu Feng, is handling the investor compensation case against Nuotai Bio, which has been officially filed in the Shanghai Financial Court [1][2] - The law firm is continuing to accept claims from other investors who have suffered losses due to the company's actions [1][2] Group 2: Financial Misconduct - Nuotai Bio's 2021 annual report contained false records, specifically a technology transfer transaction with Zhejiang Huabei, which was reported to generate revenue of 30 million yuan [3][4] - The transaction was deemed lacking commercial substance, as Zhejiang Huabei did not have the financial capability or operational capacity to utilize the technology, leading to an artificial inflation of revenue by 30 million yuan and a profit increase of 25.9516 million yuan, which accounted for 20.64% of the total profit reported for that period [3][4] Group 3: Investor Compensation Eligibility - Investors who purchased Nuotai Bio shares between April 28, 2022, and October 24, 2024, and sold or continued to hold them after October 24, 2024, are eligible to file for compensation [2][4]

Core Viewpoint - ST Nuotai, a pharmaceutical outsourcing company, engaged in financial fraud during its first year of listing on the STAR Market, resulting in a fine of 76.2 million yuan from the China Securities Regulatory Commission (CSRC) for fabricating significant false content in public offering documents [1][4][18]. Group 1: Fraud Details - ST Nuotai's fraudulent activities included falsely reporting a technology transfer income of 30 million yuan in December 2021, which was not supported by actual business substance [3][17]. - The company confirmed that the technology transfer payment from Zhejiang Huabei Pharmaceutical Co., Ltd. was funded by ST Nuotai's own capital increase, creating a closed-loop funding situation [3][17]. - The inflated revenue of 30 million yuan led to a reported profit increase of 25.95 million yuan, accounting for 20.64% of the total profit disclosed for that period [3][17]. Group 2: Regulatory Actions - The CSRC imposed a total fine of 76.2 million yuan on ST Nuotai and its actual controller Zhao Dezhong, along with five other individuals, for their involvement in the fraudulent activities [1][4][18]. - ST Nuotai's former chairman and vice-chairman were fined a combined 18 million yuan, and the company was ordered to correct its practices and received a warning [4][18]. - The Shanghai Stock Exchange publicly reprimanded ST Nuotai and its responsible individuals, prohibiting the company from applying for refinancing for five years [12][26]. Group 3: Company Background and Financial Performance - ST Nuotai was established in April 2009 and went public on the STAR Market in May 2021, previously gaining market attention due to its involvement in GLP-1 weight loss drugs [21][27]. - For the first three quarters of the current year, ST Nuotai reported a revenue of 1.527 billion yuan, representing a year-on-year increase of 21.95%, and a net profit of 444.54 million yuan, up 26.92% from the previous year [27][28]. - As of December 18, ST Nuotai's stock price was 38.38 yuan per share, with a total market capitalization of 12.1 billion yuan [27][28].